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Introduction: Lumbar chemical sympathectomy (LCS) is used principally in inoperable peripheral
vascular disease (PVD) to alleviate symptoms of rest pain and as an adjunct to other treatments for
ulcers. No guidelines currently exist in the UK for its use in PVD. The aim of this study was to evaluate the
role of LCS with regard to indications and outcomes in the UK and Irish vascular surgical practice.
Methods: Speciﬁcally designed questionnaires were sent to Vascular Surgical Society members. The
questions related to their current use of LCS including indications, outcome parameters, use in diabetics
and complications encountered.
Results: Four hundred and ninety postal questionnaires were sent out and 242 responses (49%) were
received. Seventy ﬁve percent of the respondents (n¼ 183) felt that LCS had a role in current practice.
Seventy eight percent (n¼ 144) performed less than 10 procedures per year and 3% (n¼ 5) more than 20
per year. Eighty percent (n¼ 145) were performed by anaesthetists, 12% (n¼ 23) by radiologists and 8%
(n¼ 15) by surgeons. Inoperable peripheral vascular disease with rest pain was the main indication in
over 80% of responses with 27% using it for the treatment of ulcers. Only 21% used LCS in diabetics.
Clinical improvement was used to assess the outcome following LCS in 96% of responses. Complications
included neuralgia, ureteric damage and paraplegia following inadvertent extradural injection.
Conclusion: Although no clear guidance exists for the use of LCS in PVD, the majority of respondents
continue to use it. Indications and outcomes are documented in this study of UK and Irish vascular
surgical practice.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Peripheral vascular disease (PVD) of the lower limbs is the most
common pathology seen in vascular surgical practice. The
management of patients with unreconstructable distal diseasewith
rest pain has always been difﬁcult,1,2 with the obvious endpoint
being limb amputation. Attempts to improve the quality of life by
alleviating rest pain without limb ablation have led to the devel-
opment of lumbar sympathectomy.
Lumbar chemical sympathectomy (LCS) is used primarily in the
treatment of ischemic rest pain with unreconstructable distal
vessels and in the management of arterial ulcers, but rarely for
intermittent claudication. Symptomatic improvements followingrt, Stoke on Trent ST4 4BZ,
þ44 1782 556576.
ar).
ciates Ltd. Published by Elsevier LtLCS in patients with critical leg ischemia have been demonstrated
in cohort studies and randomised controlled trials, but most have
failed to identify objective beneﬁts.14,15,21,22 LCS has also been used
in alleviating the symptoms of Paget’s disease of bone, hyperhi-
drosis, and pain associated with chronic pancreatitis and inoper-
able carcinoma of the pancreas.4,5
Although no guidelines currently exist for the use of LCS in PVD,
many vascular surgeons continue to use it. This study was under-
taken to document their indications and outcomes.2. Materials and methods
Four hundred and ninety speciﬁcally designed postal ques-
tionnaires were sent to vascular consultants and associate
specialists across the UK and Ireland using contact details from the
Vascular Surgical Society of UK (Fig. 1). Questions related to LCS and
its indications, outcomes and complications. Responses were
received from 84 vascular departments across both countries.d. All rights reserved.
Fig. 1. Questionnaire: Role of lumbar chemical sympathectomy (LCS) in peripheral vascular disease (PVD).
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Only 242 of the possible 490 (49%) questionnaires were
received. Although there were no apparent systematic differences
between the responders and non-responders, the possibility exists
that only those who believed in the role of lumbar chemical
sympathectomy replied, and those who feel it has no role did not
reply. The poor response may reﬂect the difﬁculty in deﬁning an
exact role for the procedure.
Of the 242 responses, 75% (n¼ 183) felt that LCS had a role in
current practice with only 25% (n¼ 59) disagreeing. The procedure
was performed predominantly by anaesthetists (80% (n¼ 145)) but
also by radiologists (12% (n¼ 23)) and surgeons (8% (n¼ 15)). In
some institutions, the procedure was assigned to the pain team
(n¼ 8).
With regard to indications, the majority of respondents used
rest pain with unreconstructable distal arterial disease as their
main criteria. Ulcers and trash feet were the other common indi-
cations. Some respondents considered augmenting revascularisa-
tion and lower limb amputation procedures with LCS, but use in
claudication was rare. Other indications included Raynaud’s
disease, Buerger’s disease and complex regional pain syndromes
(Fig. 2).
The number of LCS procedures undertaken by individual
vascular surgeons varied from one to forty per year and is sum-
marised in Table 1. In diabetic patients, 20% (n¼ 38) of surgeonshad used LCS with 45% (n¼ 80) willing to consider it. Thirty ﬁve
percent (n¼ 65) never used it in diabetics. Twenty two percent
(n¼ 40) would repeat LCS in the same patient.
Regarding outcome assessment following LCS, the majority used
symptomatic ‘‘clinical improvement’’ as an indicator, along with
rise in temperature and a dry foot (Fig. 3).
Complications of LCS included genitofemoral and femoral nerve
neuralgia, retroperitoneal haematoma, ureteric damage and para-
plegia secondary to inadvertent extradural injection.4. Discussion
In the UK, around 20% of people over the age of 60 have some
degree of peripheral arterial disease, and both diabetes and
smoking are contributing to an increasing incidence.3 An initial
presentation with intermittent claudication has usually been
managed conservatively with the encouragement of exercise and
cessation of smoking, together with risk factor modiﬁcation.6,7
Worsening PVD with rest pain has always been more difﬁcult to
manage when vascular reconstruction proves impossible, and
many clinicians have used lumbar sympathectomy to alleviate
symptoms and improve quality of life. More recently, prostaglandin
synthetase inhibitors have been used as an alternative to sympa-
thectomy because the results are similar, but long term beneﬁts
remain poor.8
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Fig. 2. Indications for LCS in peripheral vascular disease.
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sympathetic tone, so improving tissue oxygenation. This principle
underlies its use in ulcer healing. It also decreases pain by
interrupting sympathetic–nociceptive coupling and by a direct
neurolytic action on nociceptive ﬁbres. Lumbar sympathectomy
can be performed using both open surgical and laparoscopic
techniques,9,11,17 and non-invasively through chemical injections,
with both techniques offering similar outcomes.23 Although
surgical sympathectomy is still being carried out, LCS has largely
replaced it.
5. Evolution of LCS
LCS was ﬁrst described in 1926 when Doppler reported treating
lower limb PVD by exposing and painting the femoral artery with
phenol.13 In 1949, the British surgeon Haxton5 published results of
injecting the lumbar sympathetic chains with phenol in patients
with occlusive arterial disease. He reported considerable symp-
tomatic relief in patients with ischemic rest pain and in claudicants.
In 1970, William Reid4 wrote on the technique of phenol injection
of the sympathetic chain along with its indications and outcomes.
In 1976, anaesthesiologist Robert Boas12,13 demonstrated ﬂuoro-
scopic monitoring for positioning needles and injecting neurolytic
solutions, which forms the basis for modern LCS. In some centres,
CT ﬂuoroscopy-guided LCS has been shown to be safe and effec-
tive.24 Although surgeons were pioneers in the early development
of LCS, anaesthetists and radiologists have developed it further and
now more usually perform it.
As LCS was predominantly carried out as a palliative procedure
in inoperable PVD, assessing the outcome following LCS was by and
large measured as an improvement in the quality of life.20,21,28
Depending on the indications, the other outcome parameters
considered include healing of peripheral ulcers or improvement inTable 1
Number of lumbar chemical sympathectomies performed per year per surgeon.
No of LCS per year Responses (n¼ 183)
0–10 148 (81%)
11–20 30 (16%)
21–40 4 (2%)
40 and above 1claudication distance. A sudden increase in skin temperature in the
sock distribution has been advocated as an objective method of
assessing the outcome, though the response is temporary.26 Skin
wrinkling and relief of cutaneous allodynia have also been repor-
ted, but the majority of these assessments are immediate, tempo-
rary and unreliable.25,27
6. Lumbar sympathectomy – chemical or surgical?
Earliest reports in the literature about surgical lumbar sympa-
thectomy date back to 1924, when Adson in the USA and J. Diez in
Argentina resected the lumbar sympathetic chains in the treatment
of thromboangitis obliterans.30 Sir James Learmonth29 was subse-
quently knighted for performing operative sympathectomy on King
GeorgeVI in 1949.With advancements in technique and technology,
lumbar chemical sympathectomy has become more popular.
In 1999, Holiday and his colleagues from the Netherlands
published results from their practice which showed 1-year limb
salvage rates of 61% for surgical lumbar sympathectomy and 58%
for chemical lumbar sympathectomy.21 Recently, there has been
renewed interest in laparoscopic lumbar sympathectomy9,11 in
PVD as being more deﬁnitive and safer than chemical sympa-
thectomy. Piatko et al in 2004 showed that chemical sympathec-
tomy was equal to surgical lumbar sympathectomy in terms of
outcomes.23
7. Evidence for the efﬁcacy of lumbar sympathectomy in PVD
There have been both randomised controlled and cohort studies
investigating symptom control and long term beneﬁts of LCS. In
1975, Fyfe performed a randomised trial using phenol sympa-
thectomy vs. local anaesthetic controls in patients with intermit-
tent claudication but found no subjective or objective differences
between the two groups at 1 and 3 months.14 In 1985, Cross per-
formed a trial of LCS on 37 patients with critical limb ischemia,
documenting relief of rest pain in 66% of patients in the treatment
group and 23% in the control group at 6 months.15 In 1988, Norman
and House16 showed that surgical lumbar sympathectomy in
patients with claudication and rest pain avoided surgery in 67% of
them after 5 years. In 1994, Baker and Lamerton published results
of patients with severe PVD after lumbar sympathectomy which
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Fig. 3. Assessment of outcomes following LCS.
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recovered from trophic changes over a similar period.17 In 1995,
Mashiah18 documented symptomatic relief in 48% of patients
(n¼ 383) following chemical sympathectomy.
In 2002, Matarazzo20 published results of more than 385
patients with peripheral vascular disease undergoing surgical
sympathectomy. This trial showed improvement in symptoms (with
regard to the improvement in pain, recovery of trophic lesions,
objective and subjective rise in skin temperature) in 63% of patients
after 1 year. Verma et al in 2007 showed signiﬁcant improvement in
pain and quality of life in patients with PVD, following LCS. Multiple
single centre cohort studies have shown consistent symptom
control in many patients with end stage PVD, and trials have shown
that patient selection has played a major role.16,18,198. Patient selection for lumbar sympathectomy
Patient selection for LCS has always been challenging. van Driel
et al19 (1988) reported good results in 48% of patients with evidence
of ulcer healing and pain improvement, and poor results in dia-
betics and in patients with an ankle brachial pressure index (ABPI)
of less than 0.3. The TASC (Trans Atlantic Inter-Society Consensus)
working group suggested that there was insufﬁcient evidence to
predict which patients would beneﬁt from LCS, and recommended
that patients with an ABPI of greater than 0.3 and with superﬁcial
tissue loss were the most likely to beneﬁt from lumbar sympa-
thectomy.31 Though some authors consider an ABPI of less than 0.3
as a negative predictor, the majority of surgeons have continued to
use LCS in PVD as it often serves as a penultimate intervention prior
to considering limb amputation. In fact, Lantsberg et al published
results on a case series of patients undergoing LCS prior to below
knee amputation showing improvement in below knee skin blood
ﬂow, which enhanced stump wound healing.329. LCS – surgical preference?
Though lumbar sympathectomy has been popular since the
early 1930s, multiple studies have failed to agree on set guidelines
for patient selection and indications. In 2000, a survey of surgeons
in Scotland showed 88% of surgeons practicing LCS.10 The authors
concluded that the role of LCS would remain controversial becauseof the lack of a valid prognostic marker and technical variability,
and this has continued to be so.
Our study has shown that the majority of respondents (75%) still
believe that LCS has a role in current practice. Inoperable PVD with
rest pain remain the common indications, although some institu-
tions are using it for ulcer treatment, and a few to augment
revascularisation. LCS is predominantly performed by anaesthetists
and radiologists. The procedure is less commonly carried out by
surgeons, and newly accredited vascular surgeons have had little
exposure to this technique.
It is generally perceived that diabetic patients will have little
response to sympathectomy, but 20% of our respondents said that
they would still use it in such patients. Ninety percent of respon-
dents used clinical improvement as the primary parameter for
measuring outcome, with a rise in peripheral skin temperature
indicating an immediate response. Of the 25% of respondents who
do not believe that LCS has a role in PVD, most were of the opinion
that LCS made no difference to symptom control and outcome.10. Conclusion
Lumbar chemical sympathectomy is an inexpensive, minimally
invasive and safe procedure. Our survey has shown that the
majority of respondents to this questionnaire still believe that it has
a place in the management of peripheral vascular disease of the
lower limbs not amenable to surgical reconstruction. A randomised
controlled study comparing conservative medical management vs.
LCS in critical limb ischemia would be very useful in determining
the place of LCS in the future management of end stage lower limb
PVD, as there are currently no guidelines or solid studies which
clearly demonstrate its efﬁcacy.
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